Project Grant K08CA286755
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded $278,494 to the University of Washington effective August 1, 2025, through July 31, 2030. This K08 Career Development Award supports the training and research experience of an Assistant Professor of Medicine and primary care physician to develop expertise as an independent clinician-investigator focused on addressing cancer screening inequities. The award funds...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $178,453 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective August 8, 2025, with a completion date of July 31, 2030. The award funds a pilot randomized controlled trial to develop and test a novel behavioral intervention designed to improve engagement with vaginal dilator therapy among female cancer survivors who...
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $135,513 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025, through June 30, 2027. This award supports a mentored research training and career development initiative focused on deciphering the transcriptomic basis of chemotherapy-induced cognitive impairment (CICI), commonly referred to as "chemo fog." The project represents a...
- Federal Grant Award Summary This $197,414 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports a five-year career development and research training initiative (August 7, 2025 – July 31, 2030) at Rutgers University's School of Nursing in New Jersey. The award funds structured mentorship and skill development across five key competency areas: dyadic functioning and couple-based cancer communication; qualitative and...
- This federal Project Grant award of $161,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a pilot study by the University of Connecticut (UConn) to explore communication about sexuality and intimacy among individuals with metastatic breast cancer (MBC) and their partners. The key objectives of the study are to: 1) identify themes in MBC patients' communication about sexuality and intimacy, 2) determine if specific...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a Project Grant totaling $499,294 under the Cancer Research Manpower program (CFDA 93.398), effective September 22, 2025, through August 31, 2030. The award funds development and evaluation of ASSIST, a novel benefits navigator intervention designed to address unmet social needs—including housing, food, utility, and transportation insecurity—among pediatric cancer patients....
- Federal Grant Award Summary Rutgers The State University of New Jersey, Robert Wood Johnson Medical School (RBHS-School of Nursing) received a $222,749 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded August 1, 2025, with completion targeted for July 31, 2030. The award supports the development and pilot testing of a digital single-session intervention (SSI) designed to reduce psychological distress in adolescent siblings of...
- This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...
A NURSE-LED, COPING AND SUPPORTIVE CARE INTERVENTION TO IMPROVE PSYCHOSOCIAL OUTCOMES OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER DURING THE TRANSITION FROM CURATIVE THERAPY TO SURVEILLANCE - PROJECT SUMMARY/ABSTRACT PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC) ACCOUNT FOR APPROXIMATELY 15% OF ALL BREAST CANCER DIAGNOSES BUT ARE DISPROPORTIONATELY BURDENED WITH METASTATIC DISEASE AND BREAST CANCER DEATH DUE TO HIGH RATES OF RECURRENCE AND A LACK OF RISK-REDUCING TREATMENT OPTIONS IN THE SURVEILLANCE PHASE. THE TRANSITION TO SURVEILLANCE IS MARKED WITH DISTRESS AND PROGNOSTIC UNCERTAINTY REGARDING FEARS OF CANCER RECURRENCE AT A TIME WHEN CONTACT WITH THE ONCOLOGY TEAM DECREASES. PATIENTS WITH TNBC ARE AT GREATER RISK FOR POOR PSYCHOSOCIAL OUTCOMES AS TNBC FREQUENTLY OCCURS IN YOUNGER PATIENTS, IN BLACK AND HISPANIC PATIENTS, AND IN PATIENTS HARBORING HIGH-RISK GENETIC MUTATIONS. DESPITE THE DIRE NEEDS OF PATIENTS WITH TNBC, NO COPING AND SUPPORTIVE CARE INTERVENTIONS CURRENTLY EXIST FOR THIS POPULATION. TO ADDRESS THIS GAP, THE PROPOSED STUDY DETAILS A FIVE-YEAR PLAN TO DEVELOP, REFINE, AND PILOT-TEST A NURSE-LED, COPING, AND SUPPORTIVE CARE INTERVENTION (TRANSITIONS) TO ADDRESS THE NEEDS OF PATIENTS WITH TNBC AS THEY TRANSITION FROM CURATIVE THERAPY TO SURVEILLANCE AT MASSACHUSETTS GENERAL HOSPITAL AND THREE COMMUNITY AFFILIATES. THE AIMS OF THIS PROJECT ARE TO (1) TO DEVELOP AND REFINE TRANSITIONS BASED ON PRELIMINARY DATA WITH PATIENTS WITH TNBC, DIVERSE STAKEHOLDER FEEDBACK, AS WELL AS PATIENT FEEDBACK FROM AN OPEN PILOT STUDY (N=5-8), (2) TO EVALUATE THE FEASIBILITY AND ACCEPTABILITY OF TRANSITIONS BY CONDUCTING A PILOT RANDOMIZED CONTROLLED TRIAL (RCT) (N=75), AND (3) TO ESTIMATE THE PRELIMINARY EFFECTS OF TRANSITIONS FOR IMPROVING PSYCHOSOCIAL OUTCOMES IN THE PILOT RCT. THE CANDIDATE, DR. KATHRYN POST, ASSEMBLED A MENTOR TEAM COMPRISED OF INTERNATIONALLY RECOGNIZED INVESTIGATORS IN BEHAVIORAL INTERVENTIONS, PATIENT-REPORTED OUTCOMES, CANCER CARE (JOSEPH GREER, PHD), TNBC (LEIF ELLISEN, MD, PHD), AND SUPPORTIVE CARE TRIALS IN PATIENTS WITH BREAST CANCER (JAMIE JACOBS, PHD). A SCIENTIFIC ADVISORY COMMITTEE WILL PROVIDE GUIDANCE ON: QUALITATIVE DATA METHODS (LARA TRAEGER, PHD); EQUITY IN BREAST CANCER CARE (BEVERLY MOY, MD, MPH); NURSE-LED INTERVENTIONS IN CANCER SURVIVORSHIP (TERESA HAGAN THOMAS, PHD, BA, RN); AND BIOSTATISTICS (DUSTIN RABIDEAU, PHD). DR. POST WILL ACHIEVE HER SHORT-TERM GOALS THROUGH A COORDINATED RESEARCH AND TRAINING PLAN IN (1) BEHAVIORAL AND COGNITIVE- BEHAVIORAL-THERAPY-BASED INTERVENTION DEVELOPMENT, (2) RCT DESIGN, TESTING, AND CONDUCT, AND (3) LONGITUDINAL ASSESSMENT AND ANALYSIS. IN ADDITION TO REGULAR MENTORSHIP MEETINGS AND EXPERIENTIAL TRAINING INCLUDED IN THE RESEARCH PLAN, DR. POST WILL COMPLETE ADVANCED COURSEWORK AND DIDACTIC TRAINING, ATTEND AND PRESENT AT SEMINARS AND NATIONAL CONFERENCES, AND PUBLISH FINDINGS IN PEER-REVIEWED JOURNALS. THIS K08 PROPOSAL DETAILS DR. POST'S PLANS TO GAIN MENTORSHIP, DIDACTIC TRAINING, AND CAREER DEVELOPMENT TO FACILITATE HER TRANSITION TO RESEARCH INDEPENDENCE. DR. POST'S LONG-TERM GOAL IS TO BECOME AN INDEPENDENT INVESTIGATOR AND A LEADING NURSE SCIENTIST IN SUPPORTIVE ONCOLOGY. WITH THE ADDITIONAL TRAINING AND MENTORSHIP THIS K08 WILL PROVIDE, DR. POST WILL CONTRIBUTE TO NATIONAL AND INTERNATIONAL EFFORTS TO REDUCE SYMPTOM BURDEN AND IMPROVE THE QUALITY OF LIFE FOR PATIENTS WITH CANCER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $251.5k | 7/3/25 | ||
| Not listed | $251.5k | 7/17/24 |